- Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH studyZhou, J.; Zhou, J.; Zheng, J.; Wang, K.; Tang, K.; Lu, D.; Cui, J.; Zhu, D.; Wang, Y.; Zhao, Y.; Xing, L.; Ding, L.; Shi, X.; Shen, L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 1
- First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohortCheng, Y.; Yu, Y.; Fan, Y.; Jiang, L.; Wu, L.; Hu, J.; Wang, J.; Yao, W.; Han, Z.; Yao, Y.; Fang, J.; Sun, M.; Wang, Q.; Pan, Y.; Wu, R.; Liu, J.; Liu, Y.; Kulkarni, D.; Huang, X.; Janne, P. A.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLCPlanchard, D.; Janne, P. A.; Cheng, Y.; Lee, C. K.; Laktionov, K.; Yang, T-Y.; Yu, Y.; Kato, T.; Jiang, L.; Chewaskulyong, B.; Geater, S. Lucien; Maurel, J-M.; Rojas, C.; Havel, L.; Shepherd, F. A.; Tanaka, K.; Ghiorghiu, D.; Monterroso, E. Armenteros; Huang, X.; Yang, J. C-H.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
11阅读
